The EP3-agonist sulprostone, but not prostaglandin E2 potentiates platelet aggregation in human blood.
Schober
Lisa J
LJ
Khandoga
Anna L
AL
Penz
Sandra M
SM
Siess
Wolfgang
W
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D002951:Citrates / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000494:pharmacology; D004357:Drug Synergism; D006629:Hirudins / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D010974:Platelet Aggregation / Q000187:drug effects; D018078:Receptors, Prostaglandin E / Q000819:agonists*; D058308:Receptors, Prostaglandin E, EP3 Subtype; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D002951:Citrates; D006629:Hirudins; C545647:PTGER3 protein, human; D018078:Receptors, Prostaglandin E; D058308:Receptors, Prostaglandin E, EP3 Subtype; D014662:Vasoconstrictor Agents; C016767:sulprostone; D000244:Adenosine Diphosphate; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D003094:Collagen; D015232:Dinoprostone